IRIS Accounts Production v25.4.0.155 05699842 Board of Directors 29.2.24 28.2.25 28.2.25 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh056998422024-02-28056998422025-02-28056998422024-02-292025-02-28056998422023-02-28056998422023-03-012024-02-28056998422024-02-2805699842ns15:EnglandWales2024-02-292025-02-2805699842ns14:PoundSterling2024-02-292025-02-2805699842ns10:Director12024-02-292025-02-2805699842ns10:PrivateLimitedCompanyLtd2024-02-292025-02-2805699842ns10:SmallEntities2024-02-292025-02-2805699842ns10:AuditExempt-NoAccountantsReport2024-02-292025-02-2805699842ns10:SmallCompaniesRegimeForDirectorsReport2024-02-292025-02-2805699842ns10:SmallCompaniesRegimeForAccounts2024-02-292025-02-2805699842ns10:FullAccounts2024-02-292025-02-2805699842ns10:OrdinaryShareClass12024-02-292025-02-2805699842ns10:Director22024-02-292025-02-2805699842ns10:RegisteredOffice2024-02-292025-02-2805699842ns5:CurrentFinancialInstruments2025-02-2805699842ns5:CurrentFinancialInstruments2024-02-2805699842ns5:ShareCapital2025-02-2805699842ns5:ShareCapital2024-02-2805699842ns5:RetainedEarningsAccumulatedLosses2025-02-2805699842ns5:RetainedEarningsAccumulatedLosses2024-02-2805699842ns5:PlantMachinery2024-02-292025-02-2805699842ns5:FurnitureFittings2024-02-292025-02-2805699842ns5:MotorVehicles2024-02-292025-02-2805699842ns5:PlantMachinery2024-02-2805699842ns5:FurnitureFittings2024-02-2805699842ns5:MotorVehicles2024-02-2805699842ns5:PlantMachinery2025-02-2805699842ns5:FurnitureFittings2025-02-2805699842ns5:MotorVehicles2025-02-2805699842ns5:PlantMachinery2024-02-2805699842ns5:FurnitureFittings2024-02-2805699842ns5:MotorVehicles2024-02-2805699842ns5:WithinOneYearns5:CurrentFinancialInstruments2025-02-2805699842ns5:WithinOneYearns5:CurrentFinancialInstruments2024-02-2805699842ns10:OrdinaryShareClass12025-02-2805699842ns10:Director222024-02-2805699842ns10:Director222023-02-2805699842ns10:Director222024-02-292025-02-2805699842ns10:Director222023-03-012024-02-2805699842ns10:Director222025-02-2805699842ns10:Director222024-02-28
REGISTERED NUMBER: 05699842 (England and Wales)











UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 28 FEBRUARY 2025

FOR

RAINBOW MEDICAL ENGINEERING LIMITED

RAINBOW MEDICAL ENGINEERING LIMITED (REGISTERED NUMBER: 05699842)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


RAINBOW MEDICAL ENGINEERING LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 28 FEBRUARY 2025







DIRECTORS: G Profit
AL Profit





REGISTERED OFFICE: c/o Thompson Taraz Rand
Suite 20, New Cambridge House
Bassingbourn Road
Litlington
Cambridgeshire
SG8 0SS





BUSINESS ADDRESS: Shaftesbury Industrial Centre
Icknield Way
Letchworth Garden City
Hertfordshire
SG6 1RR





REGISTERED NUMBER: 05699842 (England and Wales)





ACCOUNTANTS: Thompson Taraz Rand Ltd
Chartered Accountants
10 Jesus Lane
Cambridge
Cambridgeshire
CB5 8BA

RAINBOW MEDICAL ENGINEERING LIMITED (REGISTERED NUMBER: 05699842)

BALANCE SHEET
28 FEBRUARY 2025

2025 2024
Notes £    £   
FIXED ASSETS
Tangible assets 5 35,996 34,646

CURRENT ASSETS
Stocks 40,000 110,000
Debtors 6 1,637,327 1,596,273
Cash and cash equivalents 122,811 18,755
1,800,138 1,725,028
CREDITORS
Amounts falling due within one year 7 (206,038 ) (114,139 )
NET CURRENT ASSETS 1,594,100 1,610,889
TOTAL ASSETS LESS CURRENT LIABILITIES 1,630,096 1,645,535

CAPITAL AND RESERVES
Called up share capital 8 100 100
Retained earnings 1,629,996 1,645,435
SHAREHOLDERS' FUNDS 1,630,096 1,645,535

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 28 February 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 28 February 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and loss account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 28 November 2025 and were signed on its behalf by:




AL Profit - Director


RAINBOW MEDICAL ENGINEERING LIMITED (REGISTERED NUMBER: 05699842)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025

1. STATUTORY INFORMATION

Rainbow Medical Engineering Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. STATEMENT OF COMPLIANCE

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006.

3. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements have been prepared under the historical cost convention.

Revenue recognition
Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company's activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Foreign currency transactions and balances
Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.
Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax
The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.
The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets
Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition
and installation.

Cash and cash equivalents
Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.


RAINBOW MEDICAL ENGINEERING LIMITED (REGISTERED NUMBER: 05699842)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 28 FEBRUARY 2025
Trade debtors
Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.
Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.
The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings
Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.
Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.
Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Leases
Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Share capital
Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends
Dividend distribution to the company's shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

RAINBOW MEDICAL ENGINEERING LIMITED (REGISTERED NUMBER: 05699842)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 28 FEBRUARY 2025

3. ACCOUNTING POLICIES - continued

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - 15% on reducing balance
Fixtures and fittings - 15% on reducing balance
Motor vehicles - 25% on reducing balance

Stocks
Stocks and work in progress are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Cost is calculated using the first-in, first-out method and includes all purchase, transport, and handling costs in bringing stocks to their present location and condition.

Financial instruments
Basic financial assets and basic financial liabilities as defined under section 11 of FRS 102, including trade and other debtors, trade and other creditors, cash and bank balances and investments in commercial paper, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

4. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2024 - 2 ) .

5. TANGIBLE FIXED ASSETS
Fixtures
Plant and and Motor
machinery fittings vehicles Totals
£    £    £    £   
COST
At 29 February 2024 80,059 30,726 5,921 116,706
Additions 7,345 374 - 7,719
At 28 February 2025 87,404 31,100 5,921 124,425
DEPRECIATION
At 29 February 2024 56,702 19,577 5,781 82,060
Charge for year 4,605 1,729 35 6,369
At 28 February 2025 61,307 21,306 5,816 88,429
NET BOOK VALUE
At 28 February 2025 26,097 9,794 105 35,996
At 28 February 2024 23,357 11,149 140 34,646

RAINBOW MEDICAL ENGINEERING LIMITED (REGISTERED NUMBER: 05699842)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 28 FEBRUARY 2025

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade debtors 75,339 56,528
Amounts owed by group undertakings 1,549,812 1,457,261
Other debtors - 754
Directors' current accounts - 72,788
VAT 7,681 6,387
Called up share capital not paid 100 100
Prepayments 4,395 2,455
1,637,327 1,596,273

At 28th of February 2025 the company was owed £1,549,812 (2024 - £1,457,261) by Rainbow Engineering Services.The debt was repaid within nine months of the year end.
The company owes Rainbow Ultrasonics Ltd £42,896 (2024 - £46,034)
The company owes Autoswitch £11,900 (2024 - £nil).
The companies are connected by virtue of owner/director in common, Mr A. L. Profit.

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade creditors 24,632 8,346
Amounts owed to group undertakings 54,796 46,034
Tax 71,147 52,903
Social security and other taxes 5,778 -
Other creditors 3,614 2,702
Directors' current accounts 39,739 1,154
Accrued expenses 6,332 3,000
206,038 114,139

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2025 2024
value: £    £   
100 Ordinary £1 100 100

9. OTHER FINANCIAL COMMITMENTS

In February 2023 the company entered into a rental lease agreement for a total amount of £19,662.39. The length of the lease is three years.

RAINBOW MEDICAL ENGINEERING LIMITED (REGISTERED NUMBER: 05699842)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 28 FEBRUARY 2025

10. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 28 February 2025 and 28 February 2024:

2025 2024
£    £   
G Profit
Balance outstanding at start of year 72,788 72,026
Amounts advanced - 762
Amounts repaid (72,788 ) -
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year - 72,788

11. RELATED PARTY DISCLOSURES

At 28th of February 2025 the company was also owed £nil (2024 - £72,788) by Mrs G. Profit. This loan is connected by virtue of Mrs G. Profit being the spouse of Mr A.L. Profit.